PARTHENOLIDE FREE BIOACTIVE INGREDIENTS FROM FEVERFEW (TANACETUM PARTHENIUM) AND PROCESSES FOR THEIR PRODUCTION

• US 20090186109A1
• Filed: 03/26/2009
• Published: 07/23/2009
• Est. Priority Date: 02/21/2006
• Status: Active Grant

• Current Assignee: Isp Investments LLC (Ashland Global Holdings, Inc.)
• Original Assignee: Integrated Botanical Technologies, LLC
• Inventors: Koganov, Michael
• Granted Patent: US 8,728,548 B2
• Time in Patent Office: Days
• US Class Current: 424/764
• CPC Class Codes: A61K 36/28 Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/16 Emollients or protectives, e.g. against radiation
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/06 Antimigraine agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 39/06 Free radical scavengers or antioxidants

Abstract

The present invention relates to bioactive ingredients that include isolated bioactive fractions derived from cell juice of fresh biomass of a feverfew (Tanacetum parthenium) plant. The bioactive fractions are either free of or substantially free of α-unsaturated γ-lactones (e.g., parthenolide). Further, the bioactive fractions have anti-inflammatory and antioxidant activity. The present invention also relates to a method for isolating a bioactive fraction that is derived from cell juice of fresh biomass of a feverfew (Tanacetum parthenium) plant and that is at least substantially free of α-unsaturated γ-lactones (e.g., parthenolide). The present invention also relates to a method for preparing a stabilized cell juice serum fraction and a stabilized concentrated cell juice serum fraction that are free of α-unsaturated γ-lactones (e.g., parthenolide). The present invention also relates to a bioactive composition that includes a mixture of one or more of the isolated bioactive fractions of the present invention.

Claims

1. A bioactive ingredient comprising:

an isolated bioactive fraction derived from cell juice of fresh biomass of a feverfew (Tanacetum parthenium) plant, wherein said bioactive fraction is either free of or substantially free of α

-unsaturated γ

-lactones, said α

-unsaturated γ

-lactones comprising parthenolide, and wherein said bioactive fraction has anti-inflammatory and antioxidant activity.

2. The bioactive ingredient according to claim 1, wherein the bioactive fraction is free of parthenolide.

3. The bioactive ingredient according to claim 1, wherein the bioactive fraction is substantially free of parthenolide.

4. The bioactive ingredient according to claim 3, wherein the bioactive fraction has a parthenolide concentration of equal to or less than about 0.01 weight percent.

5. The bioactive ingredient according to claim 1, wherein the bioactive fraction has an anti-inflammatory activity ranging from an IC₅₀ value of between about 0.01 percent (volume by volume) and about 2.0 percent (volume by volume), wherein said IC₅₀ value represents the concentration of bioactive ingredient required to decrease the speed of elastase enzymatic reaction by 50 percent.

6. The bioactive ingredient according to claim 1, wherein the bioactive fraction has an antioxidant activity ranging from an IC₅₀ value of between about 0.007 percent (volume by volume) and about 1.0 percent (volume by volume), wherein said IC₅₀ value represents the concentration of bioactive ingredient required to decrease the speed of cytochrome c reduction by 50 percent.

7. The bioactive ingredient according to claim 1 further comprising a stabilizing agent.

22. The bioactive composition according to claim 1 further comprising a stabilizing agent.

8. A method for isolating a bioactive fraction that is derived from cell juice of fresh biomass of a feverfew (Tanacetum parthenium) plant and that is substantially free of α

-unsaturated γ

-lactones, said method comprising;

providing fresh biomass of a feverfew (Tanacetum parthenium) plant;

processing the fresh biomass under conditions effective to yield a cell juice supernatant and a membrane fraction;

treating the cell juice supernatant under conditions effective to yield a first cell juice serum supernatant and a cytoplasm fraction precipitate; and

isolating the cytoplasm fraction precipitate, wherein said cytoplasm fraction precipitate is a bioactive fraction that is substantially free of α

-unsaturated γ

-lactones, wherein said α

-unsaturated γ

-lactones comprise parthenolide.

9. The method according to claim 8, wherein the step of processing the fresh biomass comprises:

separating the fresh biomass into a cell juice component and a fiber enriched material;

clarifying the cell juice component to yield a clarified cell juice component; and

separating the clarified cell juice component into the cell juice supernatant and the membrane fraction.

10. The method according to claim 8 further comprising:

clarifying the first cell juice serum supernatant under conditions effective to yield a second cell juice serum supernatant;

mixing a stabilizing agent with the second cell juice serum supernatant under conditions effective to yield a stabilized cell juice serum fraction,

wherein said stabilized cell juice serum fraction is a bioactive fraction that is substantially free of α

-unsaturated γ

-lactones, said α

-unsaturated γ

-lactones comprising parthenolide.

11. The method according to claim 10 further comprising:

concentrating the stabilized cell juice serum fraction under conditions effective to yield a concentrated cell juice serum supernatant.

12. The method according to claim 11 further comprising:

mixing a stabilizing agent with the concentrated cell juice serum supernatant under conditions effective to yield a stabilized concentrated cell juice serum fraction,

wherein said stabilized concentrated cell juice serum fraction is a bioactive fraction that is free of α

-unsaturated γ

-lactones, said α

-unsaturated γ

-lactones comprising parthenolide.

13. A bioactive ingredient comprising the cytoplasm fraction precipitate produced according to the method of claim 8, wherein said cytoplasm fraction precipitate is a bioactive fraction that is substantially free of α

-unsaturated γ

-lactones, said α

-unsaturated γ

-lactones comprising parthenolide.

14. A bioactive ingredient comprising the stabilized cell juice serum fraction produced according to claim 10, wherein said stabilized cell juice serum fraction is a bioactive fraction that is substantially free of α

-unsaturated γ

-lactones, said α

-unsaturated γ

-lactones comprising parthenolide.

15. The bioactive ingredient according to claim 14, wherein said stabilized cell juice serum fraction has an anti-inflammatory activity ranging from an IC₅₀ value of between about 0.01 percent (volume by volume) and about 2.0 percent (volume by volume), wherein said IC₅₀ value represents the concentration of bioactive ingredient required to decrease the speed of elastase enzymatic reaction by 50 percent.

16. The bioactive ingredient according to claim 14, wherein said stabilized cell juice serum fraction has an antioxidant activity ranging from an IC₅₀ value of between about 0.007 percent (volume by volume) and about 1.0 percent (volume by volume), wherein said IC₅₀ value represents the concentration of bioactive ingredient required to decrease the speed of cytochrome c reduction by 50 percent.

17. A bioactive ingredient comprising the stabilized concentrated cell juice serum fraction produced according to claim 12, wherein said stabilized concentrated cell juice serum fraction is a bioactive fraction that is free of α

-unsaturated γ

-lactones, said α

-unsaturated γ

-lactones comprising parthenolide.

18. The bioactive ingredient according to claim 17, wherein said stabilized concentrated cell juice serum fraction has an anti-inflammatory activity ranging from an IC₅₀ value of between about 0.01 percent (volume by volume) and about 2.0 percent (volume by volume), wherein said IC₅₀ value represents the concentration of bioactive ingredient required to decrease the speed of elastase enzymatic reaction by 50 percent.

19. The bioactive ingredient according to claim 17, wherein said stabilized concentrated cell juice serum fraction has an antioxidant activity ranging from an IC₅₀ value of between about 0.007 percent (volume by volume) and about 1.0 percent (volume by volume), wherein said IC₅₀ value represents the concentration of bioactive ingredient required to decrease the speed of cytochrome c reduction by 50 percent.

20. A bioactive composition comprising:

a mixture of one or more isolated bioactive fractions derived from cell juice of fresh biomass of a feverfew (Tanacetum parthenium) plant, wherein the bioactive fractions are each either free of or substantially free of α

-unsaturated γ

-lactones, said α

-unsaturated γ

-lactones comprising parthenolide, and wherein the bioactive fractions have anti-inflammatory and antioxidant activity.

21. The bioactive composition according to claim 20, wherein the one or more isolated bioactive fractions comprise bioactive fractions selected from the group consisting of Supernatant I, Supernatant II, Precipitate II (Bioactive Ingredient A), Final Supernatant, Bioactive Ingredient B, Concentrated Final Supernatant, and Bioactive Ingredient C.